CClinicalTrials.gg
CompletedNCT05455151Updated Jul 13, 2022

Hysteroscopic Injections of Autologous Endometrial Cells and Platelet-rich Plasma in Patients With Thin Endometrium

A Phase 1 interventional study of Conservative therapy and PRP injection in Thin Endometrium, sponsored by Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare. Completed at 1 site in Russian Federation. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-13.

Sponsored by Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare · Phase 1, Interventional, and Prevention

Phase
Phase 1
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The investigation is devoted to the study of the effect of the introduction of autologous platelet-rich plasma (PRP) on the thickness of the endometrium. It was found that the injection of PRP and endometrial cells resuspended in PRP into the endometrium of patients with thin endometrium leads to an increase in the proliferation of endometrial cells, and as a result, to an increase in its thickness.

Read the detailed description

The study enrolled 115 patients with thin endometrium (\<7 mm at implantation window) and infertility. The cohort was divided into groups based on the treatment regimen.

Group 1 (the control, n=30) underwent conservative therapy. Group 2 (n=42) received intraendometrial injections of autologous PRP instead of the conservative therapy. Group 3 (n=38) received identical injections after conservative therapy. Group 4 (n=5) received injections of the minimally manipulated autologous endometrial cells suspended in autologous PRP.

Injections of PRP and endometrial cells suspended in autologous PRP into basal layer of endometrium facilitate the reconstitution by enhancing cell proliferation and angiogenesis.

02

Conditions studied

  • Thin Endometrium

Keywords

  • platelet-rich plasma
  • infertility
  • endometrial cells
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18-40 years
  • Normal karyotype
  • Normal karyotype of the partner
  • Regular ovulatory and menstrual cycle
  • Endometrium \<7 mm thick as measured at implantation window
  • Availability of ≥2 vitrified blastocysts of good quality
  • History of implantation failure and/or embryo transfer (ET) cancellation due to insufficient endometrial thickness

Exclusion criteria

Exclusion Criteria:

  • Pathospermia in partner
  • Use of donor gametes
  • Premature ovarian failure
  • Internal genital anomalies
  • Systemic blood diseases and coagulopathy
  • Hemoglobin \<100 g/L
  • Platelets \<100×109/L
  • Antiplatelet/anticoagulant therapy recipient status
04

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
115 participants (actual)

Study arms

  • Active comparator
    Conservative therapy

    This is Group 1, whose patients received electrical impulse therapy using a BTL-4000 Premium G device (BTL Medical Technologies, Czech Republic) starting from day 5-7 of menstrual cycle for 10-12 days daily.

    Procedure: Conservative therapy

  • Experimental
    PRP injection

    This is Group 2, whose patients received single intraendometrial injections of autologous PRP during proliferative phase (day 6-9) of menstrual cycle.

    Biological: PRP injection

  • Experimental
    Injection of PRP after conservative therapy

    This is Group 3, whose patients received electrical impulse therapy identically with Group 1 during the first menstrual cycle. In the second cycle, the patients received autologous PRP injections identically with Group 2.

    Biological: Injection of PRP after conservative therapy

  • Experimental
    Injection of PRP with endometrial cells

    This is Group 4, whose patients received single intraendometrial injections of the minimally manipulated autologous endometrial cells suspended in autologous PRP during proliferative phase (day 6-9) of menstrual cycle.

    Biological: Injection of PRP with endometrial cells

Interventions

  • ProcedureConservative therapy

    Conservative therapy to which the patients were subjected was the effect of an electrical impulse

  • BiologicalPRP injection

    This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium

  • BiologicalInjection of PRP after conservative therapy

    This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium

  • BiologicalInjection of PRP with endometrial cells

    This intervention consisted of injecting endometrial cells suspended in prp

05

What researchers measure

Primary outcomes

  1. Change in endometrial thickness after treatment compared with control.

    Ultrasonography measurements of endometrial thickness before and after the therapy and compare the thickness. Endometrial thickness measured in mm.

    Time frame: Baseline and 2 month

  2. The Doppler-assisted detection of the uterine spiral arteries

    The number of identified vessels is counted and the percentage of detection frequency is calculated accordingly, adjusted for the McNemar's binomial test. Compare the rates of visualization of the uterine spiral arteries after therapy in all groups of patients.

    Time frame: 1 month

  3. Study of the effect of therapy on the onset of pregnancy

    Investigation of the rates of clinical pregnancies and live births in all groups. After therapy, the number of clinical pregnancy and the number of live births were calculated.

    Time frame: 9 months

  4. The content of growth factor in autologous PRP

    Investigation of the content of platelet-derived growth factor-BB (PDGF-BB) and vascular endothelial growth factor (VEGF) in autologous PRP. Relative levels of PDGF-BB and VEGF are normalized to the total protein content.

    Time frame: 3 month

  5. Phenotyping of cells isolated from endometrial biopsies

    Investigation of cellular composition in endometrial biopsy. The percentage of cells positive for markers of mesenzymal stromal cells, epithelial and endothelial cells, lymphocytes is calculated and the determination of the phenotype of cells in endometrial biopsy.

    Time frame: 3 month

06

Study locations

1 site
  • Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
    Moscow, 117997, Russian Federation
07

Registry details

Key details

Study ID
NCT05455151
Lead sponsor
Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
Collaborators
Sechenov University
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
Oct 1, 2018
Primary completion
Jan 11, 2021
Completion
Mar 1, 2021
Last update
Jul 13, 2022

Study contacts

Inna Apolikhina, MD
study director · FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov" Ministry of Healthcare of the Russian Federation
Zulfiia Efendieva, PhD
principal investigator · FSBI "National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov" Ministry of Healthcare of the Russian Federation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion